Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (PIM) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behcet's Disease. This designation represents the first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier.
The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. Behcet's Disease is a chronic, relapsing systemic vasculitis that can cause painful ulcers in the mouth and genitals, skin lesions, and inflammation in the eyes, joints, blood vessels, and nervous system. Current treatment options are often inadequate, highlighting the need for novel therapies.
Dusquetide is a first-in-class innate defense regulator (IDR) technology that modulates the body's innate immune response. It targets the intracellular signaling molecule known as PBI, which is involved in the inflammatory response. By modulating this pathway, dusquetide aims to reduce inflammation and tissue damage without suppressing the immune system entirely.
The PIM designation is a regulatory milestone that can expedite the development and review of promising new medicines. Under the Early Access to Medicines Scheme, eligible patients could receive dusquetide before it receives full marketing authorization. This is particularly important for rare diseases like Behcet's, where there is a high unmet medical need.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. The company's Specialized BioTherapeutics business segment also includes HyBryte (SGX301) for cutaneous T-cell lymphoma and SGX942 for oral mucositis. In addition, Soligenix's Public Health Solutions segment develops vaccines for ricin, filoviruses, and COVID-19.
The full press release is available at https://ibn.fm/N8oN5. For more information on Soligenix, visit their newsroom at https://ibn.fm/SNGX.
